Combined with tumor-opsonizing antibodies that retain FcγR binding capacity, SIRPα-blocking agents can effectively induce phagocytosis and display enhanced antitumor responses.32 36 45 These also provides strategy for anti-CD47 antibodies to achieve tumor selectivity, thereby reducing on-target off-tumor toxicity toward healthy CD47-expressing cells. Here, SIRPA is linked to neoplasm.